Old Web
English
Sign In
Acemap
>
authorDetail
>
Zongjun Xia
Zongjun Xia
Chinese Academy of Sciences
ALK inhibitor
Kinase
Chemistry
Mutant
Cancer research
4
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
2020
Acta Pharmacologica Sinica
Zongjun Xia
Yinchun Ji
Deqiao Sun
Xia Peng
Yinglei Gao
Yanfen Fang
Zhao Xingdong
Wang Weibo
Jian Ding
Meiyu Geng
Jing Ai
Show All
Source
Cite
Save
Citations (1)
Farnesoid X receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti-PD-1 Immunotherapy
2019
Cancer immunology research
Wenjie You
Lijun Li
Deqiao Sun
Xueqing Liu
Zongjun Xia
Shan Xue
Bi Chen
Hui Qin
Jing Ai
Handong Jiang
Show All
Source
Cite
Save
Citations (9)
Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation
2018
European Journal of Medicinal Chemistry
Kaijun Geng
Zongjun Xia
Yinchun Ji
Ruisi (Ruthy) Zhang
Deqiao Sun
Jing Ai
Zilan Song
Meiyu Geng
Ao Zhang
Show All
Source
Cite
Save
Citations (7)
An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.
2016
European Journal of Medicinal Chemistry
Zilan Song
Zongjun Xia
Yinchun Ji
Li Xing
Yinglei Gao
Jing Ai
Meiyu Geng
Ao Zhang
Show All
Source
Cite
Save
Citations (8)
1